Raphael L, Tom B H
Clin Exp Immunol. 1984 Jan;55(1):1-13.
Liposomes prepared with human LS174T colon tumour cell membranes induce specific primary xenogeneic immune responses in BALB/c splenocytes in vitro. Characterization of the adjuvant role of these liposomes was accomplished by determining the effect on immune induction of several modifications on the liposomal carrier. The results showed that the carrier effect of liposomes was mediated primarily by tumour antigens exposed on the outer surface. Trypsin treatment of the liposomes eliminated 95% of the surface protein and significantly (P less than 0.05) reduced the ability of liposomes to induce cytotoxic splenocytes. The generation of cytolytic activity with liposomes was dose-dependent, with a 10 micrograms protein threshold and a maximal response at 100 micrograms. 'Rigid' liposomes were shown to be significantly (P less than 0.05) more efficacious than fluid liposomes in inducing cytotoxicity. In addition, the data indicate that the xenogeneic cell-mediated immunity exhibits identical classes of effector cells as found in murine-murine reactions. Lymphocytes bearing the THY-1, Lyt-1 and Lyt-2 surface markers were necessary for immune induction. The role of Lyt-123 subpopulation was suggested by the inability to achieve normal cytolytic levels by reconstitution with Lyt-1 plus Lyt-2 cells. Adherent cells were, as expected, necessary for the generation of primary immunity. Indeed, the interaction of I-A+ adherent cells with liposomes for at least 8 h was required to generate subsequent maximal T cell cytotoxic activity. The phenotype of the cytotoxic effector cell was Thy-1+, Lyt-2+, and I-Ad-. If this were an allo-or syngeneic, and not a xenogeneic system, this study would be of less interest. However, when coupled with the known molecular homologies between murine and human lymphocyte antigens, these results suggest that the concept of cross species major histocompatibility complex (MHC) restriction is tenable. Thus the liposome is not only an effective antigen carrier, but also a functional adjuvant for in vitro induced cell-mediated immunity.
用人LS174T结肠肿瘤细胞膜制备的脂质体在体外可诱导BALB/c脾细胞产生特异性原发性异种免疫反应。通过确定脂质体载体上几种修饰对免疫诱导的影响,完成了对这些脂质体佐剂作用的表征。结果表明,脂质体的载体效应主要由暴露在外表面的肿瘤抗原介导。用胰蛋白酶处理脂质体可去除95%的表面蛋白,并显著(P<0.05)降低脂质体诱导细胞毒性脾细胞的能力。脂质体产生溶细胞活性具有剂量依赖性,蛋白质阈值为10微克,100微克时反应最大。“刚性”脂质体在诱导细胞毒性方面比流体脂质体显著(P<0.05)更有效。此外,数据表明异种细胞介导的免疫表现出与鼠-鼠反应中相同类型的效应细胞。带有THY-1、Lyt-1和Lyt-2表面标志物的淋巴细胞是免疫诱导所必需的。通过用Lyt-1加Lyt-2细胞重建无法达到正常溶细胞水平,提示了Lyt-123亚群的作用。如预期的那样,贴壁细胞是产生原发性免疫所必需的。事实上,I-A+贴壁细胞与脂质体相互作用至少8小时才能产生随后最大的T细胞细胞毒性活性。细胞毒性效应细胞的表型为Thy-1+、Lyt-2+和I-Ad-。如果这是一个同种或同基因而非异种系统,这项研究的意义就会小一些。然而,当与鼠和人淋巴细胞抗原之间已知的分子同源性相结合时,这些结果表明跨物种主要组织相容性复合体(MHC)限制的概念是成立的。因此,脂质体不仅是一种有效的抗原载体,也是体外诱导细胞介导免疫的功能性佐剂。